6-KThe Wire
Alpha Tau Medical Ltd. files 6-K
Filed May 11, 2026 · 2mo ago · Accession 0001213900-26-054165
Plain English
Alpha Tau Medical Ltd. announced positive interim results from its U.S. Alpha DaRT trial for recurrent glioblastoma, showing a 67% complete response rate across the initial patient cohort. The trial observed only one grade 3 serious adverse event that resolved with treatment.
Filing details
- Company
- Alpha Tau Medical Ltd.
- Ticker
- DRTS
- CIK
- 1871321
- Form type
- 6-K
- Filing date
- May 11, 2026
- Report date
- May 11, 2026
- Document
- ea0290048-6k_alpha.htm
- Size
- 35 KB